18F- DCFPyL PET/CT for Prostate Cancer
Columbia University Medical Center, New York, NY
18F- DCFPyL PET/CTPhase 2 & 3Waitlist AvailableLed by Emerson Lim, MDResearch Sponsored by Columbia UniversityEligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up3.5 years
Awards & highlights
No Placebo-Only Group
Study Summary
This trial is testing a new imaging agent, [18F] PyL, to see if it can better detect metastatic prostate lesions than standard imaging. So far it seems to be working well, but more research is needed to see if it can help predict which patients will respond to certain therapies.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3.5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3.5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-patient basis
Secondary outcome measures
To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-region basis, with regions being the prostate or prostate bed, pelvis, extra pelvis, and bones
To determine the sensitivity and specificity of 18F-DCFPyL PET/CT on a per patient and region basis
Other outcome measures
To characterize ctDNA and exosomes in patients with prostate cancer
To determine correlation with ctDNA and/or exosome levels with disease burden
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 18F- DCFPyL PET/CTExperimental Treatment1 Intervention
Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
Find a site
Who is running the clinical trial?
Columbia UniversityLead Sponsor
1,372 Previous Clinical Trials
1,782,307 Total Patients Enrolled
14 Trials studying Prostate Cancer
36,511 Patients Enrolled for Prostate Cancer
Emerson Lim, MDPrincipal Investigator
Assistant Professor of Medicine2 Previous Clinical Trials
20 Total Patients Enrolled
1 Trials studying Prostate Cancer
9 Patients Enrolled for Prostate Cancer
Matthew C. Dallos, MDPrincipal Investigator
Assistant Professor of Medicine1 Previous Clinical Trials
11 Total Patients Enrolled
Media Library
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any current openings for willing participants in this clinical trial?
"As of this moment, the clinical trial mentioned is not currently recruiting patients. This is according to the latest information on clinicaltrials.gov, which was last updated on May 6th, 2022. Although this specific study has closed recruitment, there are 1289 other trials that are still looking for participants."
Answered by AI